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ABSTRACT
Many genome-wide assays involve the generation
of a subset (or representation) of the genome fol-
lowing restriction enzyme digestion. The use of
enzymes sensitive to cytosine methylation allows
high-throughput analysis of this epigenetic regula-
tory process. We show that the use of a dual-
adapter approach allows us to generate genomic
representations that includes fragments of <200bp
in size, previously not possible when using the
standard approach of using a single adapter.
By expanding the representation to smaller frag-
ments using HpaII or MspI, we increase the repre-
sentation by these isoschizomers to more than 1.32
million loci in the human genome, representing
98.5% of CpG islands and 91.1% of refSeq pro-
moters. This advance allows the development of a
new, high-resolution version of our HpaII-tiny frag-
ment Enrichment by Ligation-mediated PCR (HELP)
assay to study cytosine methylation. We also show
that the MspI representation generates information
about copy-number variation, that the assay can
be used on as little as 10ng of DNA and that mas-
sively parallel sequencing can be used as an alterna-
tive to microarrays to read the output of the assay,
making this a powerful discovery platform for
studies of genomic and epigenomic abnormalities.
INTRODUCTION
At present, there are several types of assays to test cytosine
methylation on a genome-wide scale. Some depend on the
relative enrichment of methylated or hypomethylated
DNA, mapping back these fractions to the genome by
microarray or, more recently, massively parallel sequenc-
ing techniques. Enrichment of a certain pattern of methy-
lation can be performed using proteins binding to
methylated DNA [antibodies (1,2) or methyl-binding
domain proteins (3)], methylation-dependent restriction
enzymes [mcrBC (4)] or methylation-sensitive restriction
enzymes. The development of massively parallel sequenc-
ing promises to allow nucleotide-resolution, quantitative
analysis of cytosine methylation throughout mammalian
genomes, as demonstrated in Arabidopsis (5,6) although
as we have discussed there remain signiﬁcant practical
problems to performing such assays at present (7). These
problems include signiﬁcant cost, due to the need to
deeply resequence an entire genome but further compli-
cated by the creation of noncomplementary forward and
reverse strands, doubling the eﬀective size of the reference
genome, and the diﬃculty of mapping short, degenerate
bisulphite-converted sequences to this reference genome,
especially at unmethylated loci where the cytosines are all
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Enrichment by Ligation-mediated PCR (HELP) assay
(8) is a means of screening DNA methylation status at a
large proportion of the  2.3 million CCGG sites through-
out the genome (9). The HELP assay is based on the cre-
ation of a representation of the subset of unmethylated
HpaII fragments in the genome by ligation-mediated
PCR (LM-PCR), with the methylation-insensitive MspI
representation serving as a control for experimental
variability and genomic copy number heterogeneity.
HELP is unusual among genome-wide techniques testing
cytosine methylation for enriching hypomethylated loci
speciﬁcally, whereas most other approaches speciﬁcally
enrich methylated DNA, which constitutes the majority
of the genome (10,11) and is disproportionately comprised
of repetitive sequences (12). The HELP assay positively
identiﬁes hypomethylated loci by means of the HpaII
representation, whereas techniques that enrich methylated
DNA infer the presence of a hypomethylated locus by
means of the absence of signal, for which there can be
other, technical reasons.
Ligation-mediated (LM-) PCR is the fundamental tech-
nique used in the HELP assay. In our previous report, we
used LM-PCR to amplify the fragments in a size range
from 200 to 2000bp, with little ampliﬁcation of DNA of
<200bp (8). We show here that the use of a dual-adapter
strategy combined with optimization of PCR conditions
for high (C+G) content regions allows us to increase the
HELP assay fragment representation to include smaller
fragments. By expanding the size range of the genomic
representation, we increase the number of loci that can
be studied in the genome by  50%, especially in the
most CG-dense regions of the genome, markedly increas-
ing the resolution of this assay and demonstrating how
other assays based on genomic representations could be
improved substantially. We used the MspI representation
to discover loci with altered copy number, and that we can
use as little as 10ng of starting material for the assay.
In addition, we present data from the use of massively
parallel sequencing of the HpaII and MspI representa-
tions, showing that these new technologies oﬀer advan-
tages over prior microarray approaches. The new
high-resolution HELP assay is therefore a signiﬁcant
improvement on the prior protocol that is supported by
an opensource informatic pipeline for data analysis (13).
METHODS
Cell preparation and DNA purification
GM06990 B lymphoblastoid cells were cultured in RPMI
1640 with 15% FBS, 1% glutamine and antibiotics.
The cells were harvested and washed twice by PBS and
stored in –708C. The H1 human embryonic stem cells
(hESCs, NIH code WA01 from Wicell Research
Institute, Madison WI) were cultured on matrigel (BD
Biosciences, San Diego). Ampliﬁed hESC pluripotency
was assessed by ﬂow cytometry with SSEA4, CD24 and
Oct4 markers. Erythroid progenitors derived from hESCs
were produced as previously described (14). The hESCs
were diﬀerentiated by co-culture on immortalized
human fetal hepatocytes (FH-B-hTERT) for 2 weeks.
CD34-positive cells were then magnetically sorted and
placed in a serum-free liquid culture for two weeks. The
erythroid characteristics of the diﬀerentiated cells were
assessed by ﬂow cytometry with CD71 and CD235a
(glycophorin A) markers. Primary acute lymphoblastic
leukemia cells were obtained from Our Lady of Mercy
Cancer Center, approved by Institutional Review Board
of the Albert Einstein College of Medicine. One million
fresh CD34+bone marrow progenitors were purchased
from Allcells (Emerville, CA). DNA was extracted from
these cells and checked for purity and amount by spectro-
metry (Nanodrop, Wilmington, DE).
LM-PCR with a two adapter set
The primers used were JHpaII12 (50-CGGCTGTTCAT
G-30), JHpaII24 (50-CGACGTCGACTATCCATGAAC
AGC-30), NHpaII12 (50-CGGCTTCCCTCG-30) and
NHpaII24 (50-GCAACTGTGCTATCCGAGGGAAG
C-30). Our previous protocol (8) was modiﬁed with
the additional adapter set (NHpaII12/NHpaII24). Five
micrograms of genomic DNA were digested by either
HpaII or MspI and puriﬁed by phenol/chloroform extrac-
tion and ethanol precipitation. Each 1mg of digested geno-
mic DNA was ligated by T4 DNA ligase using four oligos
(JHpaII12 and NHpaII12, JHpaII24 and NHpaII24, each
40mM) in a ﬁnal volume of 33ml. The ligated genomic
fragments were diluted and used as the template for
the LM-PCR. The optimization of PCR conditions for
LM-PCR was performed using our prior PCR conditions
(8) with/without betaine or dimethyl sulfoxide. PCR pro-
ducts were assessed by gel electrophoresis and puriﬁed
using a PCR puriﬁcation kit (Qiagen). The concentrations
of PCR products were measured by spectrometry. The
intensities of DNA from gel images were processed using
ImageJ and Photoshop (Adobe).
To improve the PCR conditions, we tested higher con-
centrations of magnesium, and explored the use of betaine
as a means of improving the ampliﬁcation of (G+C)-rich
templates (15). Dimethyl sulfoxide was also tested with
and without betaine, but this failed to enhance short frag-
ment ampliﬁcation (data not shown).
Array design, hybridization and data analysis
We custom-designed two microarrays (Roche-
NimbleGen, Inc.) for these experiments. One interrogated
the 1% of the genome studied by the ENCODE consor-
tium in their pilot phase using oligonucleotides for each
of the 18529 HpaII/MspI fragments of 50–2000bp in
these ENCODE regions (16). The second tested the
>1.32 million loci throughout the human genome that
have HpaII sites 50–2000bp apart and have unique
sequences between them that allow oligonucleotide
design. The HELP samples were labeled for microarray
analysis as described previously (17) using Cy3- or
Cy5-conjugated random primers. The HpaII and MspI
representations were co-hybridized to the microarray
and scanned to quantify the 532- and 635-nm ﬂuorescence
at each oligonucleotide on the microarray. The quantile-
normalized HpaII/MspI log2 ratios were calculated as
3830 Nucleic Acids Research, 2009, Vol. 37,No. 12previously described (13). We added a category of inter-
mediate methylation to our analysis by deﬁning all HpaII
signals falling below the 99% centile of the distribution of
random probes when scanning the HpaII channel, lower-
intensity signals in which we could assign methylation
status with less conﬁdence. Those signals exceeding the
99% centile were assigned as hypomethylated, while
methylated loci were deﬁned as previously described (13).
Correlation of genomic annotations with HELP cytosine
methylation data
The start and end positions of MspI fragments were
computationally calculated from the hg17 assembly of
the human genome sequence at the UCSC Genome
Browser (genome.ucsc.edu). Using these DNA sequences,
their base compositional characteristics [(C+G) mono-
nucleotide percent, CG dinucleotide frequency per 1kb]
were computationally calculated. The genomic positions
of the MspI fragments were used to quantify the overlap
with annotations such as CpG islands (cpgislandExt
table), CG clusters (18), retroelements (rmsk table) and
the 2-kb region ﬂanking refSeq transcription start sites.
Use of limited amounts of starting material
Ten nanograms of genomic DNA (representing  2000
mammalian diploid cell equivalents) from human mela-
noma samples were digested overnight by HpaII or
MspI (New England Biolabs, Inc., Ipswich, MA) in sepa-
rate 20-ml reactions. The digested DNA fragments were
puriﬁed by phenol/chloroform/isoamyl alcohol (25:24:1
by volume, pH 5.2, Thermo Fisher Scientiﬁc Inc.,
Waltham, MA) and ethanol precipitated in the presence
of glycogen. After washing with 70% ethanol, the DNA
pellet was resuspended in 5ml of Tris–HCl (pH 8.0).
Overnight adapter ligation was set up in a 10-ml reaction,
scaling the proportional amount of adapter down by a
factor of 30 compared with 1mg HELP, with T4 DNA
ligase (Invitrogen Corp., Carlsbad, California). Adapter-
ligated DNA fragments were ampliﬁed by two rounds of
PCR [67mM Tris–HCl, 4mM MgCl2, 16mM (NH4)2SO4,
0.35% b-mercaptoethanol, 0.5mg/ml BSA, Taq DNA poly-
merase] using 728C for 10min, 15 cycles of 958C for 30s
and 728C for 3min, with a ﬁnal extension of 728C for
10min. For the ﬁrst round of PCR, 2.5ml (MspI) or 5 ml
(HpaII) of the adapter ligation mixture was used in a
100-ml reaction, of which 1ml of PCR product was used
for a second 100-ml reaction.
Analysis of DNA copy-number variation using the MspI
representation
The analysis of HELP data used the published analytical
pipeline mentioned earlier (13). The MspI and HpaII
signal intensities were summarized for each HpaII frag-
ment as the average of its component probe-level signal
intensities. Background noise thresholds were calculated
using random probes as 2.5 median absolute deviations
(MAD) above the median of MspI and HpaII signal inten-
sities. Those fragments with HpaII above background but
MspI below background were removed from considera-
tion. A subset of fragments (those between 250 and
1000bp) was then selected and centered to align the dis-
tribution ranges, with further removal of datapoints that
exceeded 2 MADs from the center. Log ratios of MspI
signal intensities were calculated for the test sample as a
function of a normal cell type. The data were then divided
by chromosome and analyzed for copy-number variation
using DNAcopy (19), available through BioConductor
for the R Statistical Package. Copy-number array
(CNA) objects were smoothed and circular binary seg-
mentation applied, with default parameters and change
points <1 standard deviation removed.
Massively parallel sequencing of HELP representations
To eliminate adapters from LM-PCR products, we
digested the puriﬁed LM-PCR product with MspI and
concentrated the digested product using isopropanol
precipitation. The digested product was loaded onto a
5% acrylamide gel, which was run to resolve DNA frag-
ments in the <1000-bp size range. The DNA in the gel
was visualized using visible spectrum transillumination
following staining with SYBR Gold (Invitrogen), allowing
us to excise the fragments of  100–600bp in size, in doing
so eliminating the LM-PCR adapters. The DNA was
extracted from the gel pieces using Miniprep columns
(Qiagen), following which the eluted DNA was precipi-
tated by isopropanol and puriﬁed with the PCR puriﬁca-
tion kit (Qiagen). Illumina libraries were prepared using
their standard protocol, and single end sequencing was
performed with a single lane per library, 47bp per read.
The ﬁrst 32bp were aligned to the reference genome using
ELAND (Illumina), and these alignments were analysed
using a local copy of the UCSC genome browser database
and a downloaded copy of the human genome sequence
(hg18 release). All HpaII sites in the genome were identi-
ﬁed using a custom set of PERL and BASH shell scripts
and loaded into a MySQL database. The HpaII site loca-
tions were then compared to the genomic loci correspond-
ing to the Illumina reads using custom PERL scripts
and modules based on the DBI PERL MySQL interface.
The number of reads per locus (excluding those not start-
ing with CGG) was also calculated using MySQL queries
after the locations of the Illumina reads were loaded
into the MySQL database. The HpaII representation
was normalised in terms of that produced by MspI using
the sequencing equivalent of the microarray intensity-
dependent ratio (20) of the components as follows:
H 2
[(H–M)/(H+M)]+M (2
[(H–M)/(H+M)] – 1), where
H=number of HpaII reads and M=number of MspI
reads. The results of these HELP and HELP-seq assays
were compared against bisulphite MassArray (Sequenom)
data from the KCNQ1 promoter region using primers and
conditions described in Supplementary Table 1.
RESULTS
Our original assay failed to represent HpaII/MspI
fragments <200bp despite their relative abundance in
the genome, as shown by our in silico digestion of the
human genome at HpaII/MspI digestion sites (Figure 1).
Of all of the HpaII/MspI fragments in human DNA,
Nucleic Acids Research, 2009,Vol.37, No. 12 383144.5% of fragments in the 200–2000-bp range are repre-
sented in the original HELP assay, while the 22.5% in the
50–200-bp range were not generated using our original
protocol (Table 1). We considered two possible reasons
for this. First, the regions with HpaII/MspI CCGG sites
at higher frequency are enriched in (C+G) mononucleo-
tide content, making them relatively diﬃcult to amplify by
conventional PCR techniques. The (C+G) content of the
HpaII/MspI fragments of 50–2000-bp averages 60.0%, in
contrast to the 47.7% for 200–2000-bp fragments. Second,
the presence of a ligated adapter sequence may cause
intramolecular self-annealing for shorter fragments prefer-
entially, preventing PCR ampliﬁcation of these hairpin
(panhandle) structures (21). To test the second hypothesis,
we added a second adaptor for the ligation step. This is
expected to provide the ligated product with heterologous
ends at 50% frequency (Figure 2a), preventing intramole-
cular annealing in this subpopulation of molecules. We
ﬁnd that the addition of the second adapter shifts the
size range of PCR products compared with the use of a
single adapter (Figure 2b). We conclude that the use of a
single adapter for genomic representations fails to amplify
fragments <200bp because of a strong panhandle eﬀect, a
problem alleviated by the use of heterologous adapters.
These improvements in size range representation came
at the expense of yield, which may be due to the increased
(C+G) mononucleotide content of the template. By
increasing the concentration of magnesium and introdu-
cing betaine to the PCR reaction (Figure 2c), we could
generate amounts of PCR product comparable to the
original protocol. The ampliﬁcation products shown in
Figure 2d include the adapter sequences ( 50bp), indicat-
ing that we are also amplifying products  50bp in size
while preserving our ability to amplify up to 2000bp.
Our next concern was whether the shorter fragments
generated could be labeled and hybridized to a microarray
as successfully as larger fragments. We custom-designed
a NimbleGen DNA methylation 385K microarray
(Roche-NimbleGen Inc.) using oligonucleotides for each
of the 18529 HpaII/MspI fragments of 50–2000bp in
the ENCODE regions of the genome (16). We prepared
HpaII and MspI representations from the GM06990
cell line using the optimized conditions described
above (Figure 2d), labeling the representations by
random priming and co-hybridizing the labeled represen-
tations to the microarray. This customized ENCODE
array also included a set of 10100 oligonucleotides repre-
senting random sequences. To assess the microarray data,
we deﬁned the background ﬂuorescence level using a
threshold of 2.5 median absolute deviations (2.5 MAD)
above the median intensity of these control oligonucleo-
tides. We have found this value to deﬁne consistently the
distinctive population of loci in HpaII representations that
does not amplify due to local methylation, and applied the
same parameter to deﬁne signal intensities in the MspI
channel, indicating loci that have failed to amplify ade-
quately (Supplementary Figure 1). In the current experi-
ment, we observed a failure rate of 5–9% in total, but only
2–4% were in the size range of 50–199bp (Supplementary
Figure 1). When the HpaII representation was studied,
we observed a bimodal distribution, demonstrating that
the two-adapter HELP method discriminates between
methylated and unmethylated loci (Supplementary
Figure 1).
Table 1. Annotation of human HpaII/MspI fragments in high-resolution HELP
Original representation Added representation Combined representation
Total Size range/bp 200–2000 50–199 50–2000
Number 1016980 514387 1531367
CpG islands Number overlapped 23881 23716 27035
Proportion represented 87.00% 86.40% 98.50%
Mean number of fragments/locus 1.6 3.9 5.5
CG clusters Number overlapped 42226 39206 43740
Proportion overlapped 95.10% 88.30% 98.60%
Mean number of fragments/locus 2.3 3.9 6.3
refSeq Number overlapped 16848 14923 17223
promoters  Proportion overlapped 89.10% 78.90% 91.10%
Mean number of fragments/locus 2.6 4.2 6.8
 2kb ﬂanking transcription start site.
Figure 1. In silico analysis of human HpaII/MspI fragments by length.
The numbers of fragments computationally generated from the refer-
ence human genome sequence were plotted by length, demonstrating
higher frequencies of shorter fragments. The three peaks observed
(at 69, 135 and 204bp) are due to the presence of Alu SINEs
(mainly AluS and AluY), peaks that can also be observed in the ethi-
dium bromide staining of the MspI reference representation in Figure 2
(b, c).
3832 Nucleic Acids Research, 2009, Vol. 37,No. 12In addition, the scatterplots and Pearson’s correlation
coeﬃcients for log2 MspI intensities and HpaII/MspI
intensity ratios illustrated that both technical and
biological replicates show high correlation in MspI
intensities (98–99%) and HpaII/MspI ratios (95–99%)
(Supplementary Figure 1). We conclude that the labeling
and hybridization of the additional representation of
shorter fragments is as eﬃcient and reproducible as the
original method.
We then used a genome-wide microarray consisting
of >1.32 million loci for the human genome to test the
cytosine methylation pattern in human embryonic stem
cells. We show the results of the methylation patterns
observed in Figure 3. We see that CG-dense loci [CpG
islands or CG clusters (18)] and promoters are less methy-
lated than the CG-depleted sequences within gene bodies
and intergenic sequences. These are results concordant
with prior expectations (22) and demonstrate the assay
to be able to report expected patterns of methylation in
a variety of sequence contexts.
Adaptation of protocol to limited starting amounts of
DNA: nanoHELP
A limitation in many epigenomic assays is their require-
ment for large amounts of sample. As the HELP assay
involves a PCR ampliﬁcation step, we tested whether we
could use substantially less starting amounts of DNA and
still get reproducible results. We performed the assay
using 1mg of DNA as a reference sample and 10ng of
the same DNA for LM-PCR, using two rounds of ampli-
ﬁcation with 15 cycles per round to stay within the
Figure 2. Optimization of the HELP protocol for high-resolution repre-
sentations. In (a) we show data representing the results of the two-
adapter approach. Homologous ends using a single adapter can
produce a hairpin structure in short fragments, an event that should
be eliminated in 50% of fragments when using dual adapters to create
heterologous ends. In (b) we demonstrate that the use of a single adap-
ter (J, N) fails to create the smaller fragments seen when used together
(JN, replicate experiments annotated as JN1, JN2). We also show that
the type of buﬀer used, Mg
2+ concentration and betaine combine to
improve representation and yield (b, c). The original (red) and
improved (blue) conditions for creating representations are compared
in (d) as densitometric plots of gel electrophoreses, demonstrating the
shift toward representation of PCR products of  100bp. As the adap-
ters contribute  50bp to the size of the product, the representation
of HpaII/MspI fragments in the genome includes those as small as
50bp in this new protocol.
Figure 3. The distribution of cytosine methylation by genomic com-
partment. The distribution of cytosine methylation using the new
high-resolution genome-wide HELP microarray is categorized as hypo-
methylated (white), methylated (black) and intermediate (grey) based
on thresholds categorising the bimodal distribution of HpaII/MspI
ratios. The results show relative hypomethylation of CpG islands or
CG clusters (18) whether at promoters, within gene bodies or interge-
nically compared with other sequences. This is consistent with expecta-
tions for the distribution of methylation and indicates that the assay is
capable of deﬁning methylation states in a range of genomic contexts.
Nucleic Acids Research, 2009, Vol.37, No. 12 3833linear stage of ampliﬁcation. We show in Figure 4 that we
can amplify the DNA robustly from the 10-ng samples,
and that microarray hybridizations generate correlations
of HpaII/MspI ratios measured by R-values in excess of
0.96. We conclude that HELP can be used on amounts
of DNA that represent approximately the amount in 2000
cells, and is likely to be amenable to further scaling to even
more limited starting amounts.
Simultaneous copy-number analysis: HELP-CNV
We investigated whether the HELP data could simulta-
neously be used to provide copy-number information,
given that the MspI representation should be unaﬀected
by cytosine methylation and instead dependent on the
amount of DNA present. In a manner analogous to the
ROMA technique (23), we compared the MspI (methyla-
tion-insensitive) representations of two diﬀerent samples.
One sample was a primary leukemia sample from a human
subject that we have previously studied (24) and found
to have copy-number changes by array comparative geno-
mic hybridization (aCGH), the other was a normal
CD34+hematopoietic stem cell sample used as a control
with presumed minimal copy-number variability. The
copy-number variation analysis of HELP data (HELP-
CNV) identiﬁed the same patterns of ampliﬁcations
and deletions on chromosome 20 found using aCGH
(Figure 5). The HELP-CNV approach allows the data
generated as part of a HELP assay to harvest a second
source of information about DNA copy number while
testing cytosine methylation genome wide, a useful com-
bination for diseases such as cancer.
HELP studies using massively parallel sequencing:
HELP-seq
The development of massively parallel sequencing has
provided an alternative to microarrays for measuring
the enrichment of genomic representations following chro-
matin immunoprecipitation (ChIP-seq). We sought to test
whether the HELP representations could allow similar
mapping of hypomethylated loci. Contaminating frag-
ments in the assay can be recognized because they lack
the HpaII/MspI site remnant (CGG) that starts each
sequence read following the digestion and end-polishing
when creating the libraries. In Table 2 we show a summary
of the results for each library, including a proportion
( 3%) in each library that starts with a CGG but is not
located at a canonical HpaII site (CCGG) in the reference
genome sequence, indicating that we are identifying a sub-
stantial number of polymorphic HpaII sites in this ES cell
DNA sample.
When we map these sites to the genome we observe
‘piling up’ of reads at HpaII sites, indicating their enrich-
ment by the representation. We note that the control MspI
representation is not enriched equally at all sites, a ﬁnding
Figure 4. HELP with limited amounts of DNA template: nanoHELP. To test whether HELP could be used with more limited quantities of DNA
than previously attempted, we generated representations using 1mg and 10ng of material from the same DNA sample, using the PCR conditions
shown (a). It is apparent that the conditions used generate representations from the 10-ng samples similar in quantity to those from the 1mg sample.
These representations were used for HELP microarray hybridization to test whether the smaller sample amounts reproduced the methylation proﬁle
of the 1mg sample. HpaII/MspI log ratios were correlated for the 1mg control and the three experimental replicates of 10ng each. We found the
limited sample quantities to generate proﬁles highly concordant with the 1mg control, with R-values exceeding 0.96 in all cases (b). We conclude that
HELP representations can be generated with DNA amounts equivalent to the yield from thousands of diploid mammalian cells.
3834 Nucleic Acids Research, 2009, Vol. 37,No. 12similar to those we have observed previously using micro-
array-based approaches (13). The HpaII representations
are also heterogeneous but this is subject to the additional
inﬂuence of cytosine methylation. We normalized the
HpaII representation in terms of the MspI data and plot-
ted wiggle tracks for the resulting data. In general,
we found the microarray-based HELP and the HELP-
seq data to be strongly concordant, as represented in
Figure 6. We noted that the discordance of the assays
appeared to be mostly in terms of HELP-seq identifying
additional hypomethylated loci, such as the alternative,
non-CpG island, non-CG cluster (18) promoter of
KCNQ1, which appears to become hypomethylated in ery-
throid progenitor cells (Figure 6). We tested this locus
using bisulphite MassArray and conﬁrmed its hypomethy-
lation (Figure 6), indicating that HELP-seq is more sensi-
tive than microarray-based HELP in identifying
hypomethylated loci. We note that HELP-seq allows map-
ping of sequences shorter than the 50-bp minimum that
we can represent on a microarray, and can thus give
more detailed information about CG-dense regions of
the genome than when using microarrays.
DISCUSSION
Genomic representations by LM-PCR are used by a
number of diﬀerent applications, including representa-
tional oligonucleotide microarray analysis (ROMA) (23),
high-density SNP microarrays (25) and other epigenomic
assays testing cytosine methylation (26–28). The HELP
assay uses representations from HpaII to distinguish
methylated from unmethylated loci in the genome, with
a concurrent MspI representation deﬁning the full range
of potential HpaII-ampliﬁable fragments. The more frag-
ments that can be represented, the greater the level of
detail we can achieve in ROMA, SNP or epigenomic
analyses. By increasing the representation of shorter frag-
ments using dual adapters and modiﬁed PCR conditions,
we achieve greater coverage of CG-dense regions in parti-
cular. By computational analysis, we show that the pro-
portional coverage for CpG islands or our updated
deﬁnition of CG clusters (18) approaches the maximum
possible (98.5% and 98.6%, respectively, Table 1). In
addition, the number of fragments at each CG-dense
locus and refSeq promoter is increased 2- to 3-fold com-
pared with the previous representation, which enables a
more detailed analysis of DNA methylation in these pro-
moter regions. We demonstrate that these shorter frag-
ments (50–200bp) can be labeled with the random
priming technique and hybridized to microarrays with
signal ranges comparable to those of larger fragments.
Our practical lower limit for microarray analysis is con-
strained by the size of the oligonucleotides we use
( 50nt), making it diﬃcult to represent fragments smaller
than the oligonucleotides themselves. For massively par-
allel sequencing applications, the sequences generated are
Figure 5. The MspI representation in a HELP assay can be used to detect copy-number variation: HELP-CNV. The MspI proﬁle generated as part
of the HELP assay is not aﬀected by CG dinucleotide methylation and should instead be inﬂuenced by the amount of template available. We tested
whether we could exploit this to detect copy-number variability (CNV) in a leukemia cell sample known to have ampliﬁcations and deletions (24)
shown by microarray comparative genomic hybridization [aCGH, (a)]. In this representation of chromosome 20, we see regions with ampliﬁcations
(increased log2 signal) and deletions (decreased signal). We performed a HELP assay on the same leukemia DNA sample and compared the MspI
signal from each locus with the MspI signal from a HELP assay performed on a reference cell sample (normal CD34+ hematopoietic stem cells).
These results are shown in (b). By performing the same segmentation analysis as for aCGH to deﬁne blocks of signal intensities, we found the
MspI HELP data identify the same regions of ampliﬁcation and deletion in these leukemic cells. HELP can thus give information about CNV
simultaneously with its cytosine methylation analysis.
Nucleic Acids Research, 2009, Vol.37, No. 12 3835generally shorter ( 35bp) and need only be long enough
to allow accurate mapping to the reference genome,
increasing the number of testable loci compared with
microarrays.
This new representation allowed us to design high-
resolution HELP microarrays for the human, mouse, rat
and cow genomes, each representing over 1 million loci
throughout these genomes. By using a high-density plat-
form, we can represent these loci on a single microarray,
allowing analysis of the entire genome in a single hybrid-
ization experiment. We performed a high-resolution
HELP assay on human ES cells to test how the cytosine
methylation patterns observed correlate with genomic
annotations. We found relative hypomethylation of CpG
islands and CG clusters compared with other sequences,
and less methylation at promoters compared with gene
bodies or intergenic regions, patterns consistent with
prior observations about the distribution of cytosine
methylation (22).
When moving epigenomic assays to the clinical setting,
a critical issue to address is the potential to use the limited
sample amounts that can be acquired from biopsies.
As the generation of genomic representations in the
HELP assay involves PCR, we tested whether the ampli-
ﬁcation step could allow us to generate adequate amounts
of material from limited starting amounts of DNA.
We used 10ng of DNA in our studies as an amount repre-
senting approximately 2 10
3cells, and found the proﬁles
generated to be highly comparable with those generated
using our usual microgram quantities of starting material.
We conclude that the HELP assay can be used on rela-
tively limited numbers of cells. Our ongoing studies are
testing whether we can decrease the starting amounts of
DNA still further.
We also found that the MspI representation on its own
allows an accurate and detailed analysis of copy number.
This approach is similar to the published ROMA tech-
nique (23) in that it uses genomic representations by
methylation-insensitive restriction enzymes, but is sub-
stantially higher resolution with >1.32 million loci repre-
sented. With MspI/HpaII sites more frequent in (C+G)
mononucleotide-rich regions which tend also to be
more gene-rich (9), the MspI representation oﬀers
selectively higher resolution in gene-rich regions,
which is potentially advantageous. The HELP-CNV appli-
cation allows DNA to be tested for cytosine methylation
and copy-number variation simultaneously, a valuable
tool especially in cancer research, in which epigenomic
alterations (29) and copy-number changes (30) are
frequent.
A major advantage of HELP-seq compared with micro-
array-based HELP appears to be one of sensitivity of
detection of hypomethylated loci. We believe that this is
due to the lower background noise for sequencing com-
pared with microarrays, which always generate a ﬂuores-
cence intensity reading whether there is genuine signal
present or not. There are other potential advantages
of HELP-seq, including the capacity to detect allelic dif-
ferences in methylation, information about repetitive
sequences and the ability to detect events in HpaII frag-
ments smaller than the 50-bp lower limit for microarray
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3836 Nucleic Acids Research, 2009, Vol. 37,No. 12Figure 6. Adaptation of the HELP assay to use massively parallel sequencing: HELP-seq. Instead of using microarrays to map the representations to
their genomic source, we sequenced the ends of the fragments using massively parallel sequencing (Illumina). We show the promoter region of the
KCNQ1 gene as an example of the concordant data obtained, with hypomethylated sites represented as an upward/positive peak and methylated as
downward/negative, in both the microarray-based (HELP) and Illumina-based (HELP-seq) assays. The HELP data are represented by quantile-
normalized HpaII/MspI log2 ratios (13) while the HELP-seq data are represented by the number of HpaII reads per locus normalised to MspI reads
for the same locus as described in the main text. Both embryonic stem (ES, red) and derived in vitro-diﬀerentiated erythroid progenitor (blue) cells
are shown. The upstream (left) promoter of KCNQ1 is hypomethylated in both cell types, with a broader region of hypomethylation in erythroid
compared with ES cells in both the HELP and HELP-seq studies. The downstream promoter appears to be methylated in ES cells in both assays,
but microarray-based HELP weakly indicates hypomethylation in erythroid cells, whereas HELP-seq shows a strong hypomethylated signal in these
cells. To determine which technique was more accurate, we performed validation using bisulphite MassArray (bottom), conﬁrming the underlying
hypomethylation of this locus in the erythroid and not ES cells, and demonstrating that HELP-seq oﬀers improved capacity to identify sites of
hypomethylated DNA in the genome.
Nucleic Acids Research, 2009, Vol.37, No. 12 3837studies. We also note that we identiﬁed a substantial
number of HpaII sites ( 3%) that are not present in the
reference human genomic sequence, variability that would
not be captured by or that would cause errors in micro-
array-based approaches.
The ideal assay to test cytosine methylation would test
every CG dinucleotide individually and quantitatively
throughout the genome, preserving information about
cis-relationships of methylation states between CGs, and
allowing high sample throughput. No such assay exists
at present. While massively parallel sequencing-based
approaches promise to make nucleotide-resolution studies
possible (2,5,6,31), at present their sample quantity
demands and costs remain daunting. The HELP assay
falls into a category of assays that act to screen the
genome at lower resolution, the ‘discovery’ step that
deﬁnes loci for more detailed, nucleotide-resolution
studies. Other assays in this category include methyla-
tion-dependent restriction enzyme assays (32) and aﬃ-
nity-based assays using antibodies (1) or other natural
methyl-binding proteins (3). The comparative advantages
of HELP include its capability of using a single array and
the easy technical validation of results, as the focus is
solely on methylation at the HpaII/MspI sites (CCGG)
generating the representations. While HpaII/MspI sites
constitute only  8% of the CG dinucleotides in the
genome (9), the presence of methylation ‘states’ in cis
that may extend over as much as 1kb (33) allow discovery
assays to ﬂag interesting regions by testing a subset of
CGs. When we measure the proportion of CGs in the
human genome residing in proximity to the HpaII sites
on the HELP microarray we used, we ﬁnd that approxi-
mately two-thirds are within 1kb of these sites (Supple-
mentary Figure 2). While epigenomic discovery
approaches directly test only a minority of CGs, they
have the potential of ‘ﬂagging’ the majority of CGs
in the genome. We conclude that the high-resolution
HELP assay is technically simple and robust and oﬀers
the capacity to test both the epigenome and copy-
number variability, and has the potential for use with lim-
ited numbers of cells and adaptation to massively parallel
sequencing platforms.
ADDENDUM
While this manuscript was in review, an assay fundamen-
tally similar to HELP-seq, described as Methyl-seq, was
published by Brunner et al. (34).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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